AbbVie
Contact information
- A. Health Biotechnology
- Areas of activity
- Biodrugs
- Therapeutic areas
- Analgesia & Pain
- Dermatology
- Infectious diseases
- Immunology
- Oncology
- Digestive system and hepatology
- Central nervous system
- Respiratory and pulmonary system
AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
AbbVie is a patient-centric company; our starting point is a deep understanding of the disease.
Our products treat some of the world's most complex illnesses such as Rheumatoid Arthritis, Crohn's Disease, Psoriasis, Hidradenitis Suppurativa, Ankylosing Spondylitis, Juvenile Idopatic Arthritis, Psoriatic Arthritis, Chronic Kidney Disease, Advanced Parkinson's Disease, Respiratory Syncytial Virus prevention, HIV, hepatitis C virus, and Prostate Cancer.
Our pipeline includes more than 30% biologicals and more than 20 compounds in phases II and III of clinical development, and we have hundreds of patents for new discoveries in the areas of Immunology, Neuroscience, Renal Health, Oncology and Women?s Health. Our experience in both small molecules and biologicals gives us the flexibility needed to find the most ideal solution for a given illness.
We collaborate with university professors, researchers, health professionals, health authorities and patient advocates to offer new sustainable medical solutions and create services with added value that make a difference in patients' lives.
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Development phase |
|---|---|---|---|
| Telisotuzumab vedotin (ABBV-399) | Biodrugs/ Drugs | Oncología | P III |
| Skyrizi | Biodrugs/ Drugs | Inmunología | P III |
| Lutikizumab | Biodrugs/ Drugs | Inmunología | P II |
| Epcoritamab | Biodrugs/ Drugs | Oncología | P III |
| Elezanumab (ABT-555) | Biodrugs/ Drugs | Sistema nervioso central | P II |
| ALPN-101 | Biodrugs/ Drugs | Inmunología | P II |
| Eftoza | Biodrugs/ Drugs | Oncología | P I |
| AGN-151607 | Biodrugs/ Drugs | P II | |
| AL002 | Biodrugs/ Drugs | Sistema nervioso central | P II |
| ABBV-927 | Biodrugs/ Drugs | Oncología | P II |
| ABBV-CX-2029 | Biodrugs/ Drugs | Oncología | P II |
| ABBV-916 | Biodrugs/ Drugs | Sistema nervioso central | P II |
| ABBV-647 | Biodrugs/ Drugs | Oncología | P I |
| ABBV-637 | Biodrugs/ Drugs | Oncología | P I |
| ABBV-400 | Biodrugs/ Drugs | Oncología | P I |
| ABBV-383 | Biodrugs/ Drugs | Oncología | P I |
| ABBV-368 | Biodrugs/ Drugs | Oncología | P I |
| ABBV-181 | Biodrugs/ Drugs | Oncología | P I |
| ABBV-155 | Biodrugs/ Drugs | Oncología | P I |
| ABBV-154 | Biodrugs/ Drugs | Inmunología | P II |
| ABBV-151 | Biodrugs/ Drugs | Oncología | P II |